Table 3.
Multivariate regression model assessing the associations between 6MWD and SSc characteristics
| β | (95% CI) | p | |
|---|---|---|---|
| Male (vs female) | 58.9 | (22.6; 95.2) | 0.002 |
| Age (per 1-year increment) | –2.8 | (–3.9; –1.7) | <10–3 |
| Disease duration since diagnosis (per 1-year increment) | –0.7 | (–2.5; 1.0) | 0.42 |
| BMI (per 1-kg/m2 increment) | –2.7 | (–5.1; –0.2) | 0.03 |
| Smoking history (vs no history) | –8.2 | (–33.9; 17.5) | 0.53 |
| History of venous thrombosis (vs no history) | –10.8 | (–48.6; 26.9) | 0.57 |
| History of arterial thrombosis (vs no history) | –39.6 | (–77.9; –1.4) | 0.04 |
| dcSSc (vs lcSSc) | –22.7 | (–57.6; 12.2) | 0.20 |
| PAH (vs no PAH) | –79.2 | (–129.7; –28.8) | 0.002 |
| ILD (vs no ILD) | 0.15 | ||
| Limited ILD | 22.0 | (–6.9; 50.9) | |
| Extensive ILD | –14.7 | (–55.8; 26.4) | |
| Joint symptoms (vs no symptoms) | –16.5 | (–41.6; 8.6) | 0.20 |
| Muscle symptoms (vs no symptoms) | –7.5 | (–40.6; 25.7) | 0.66 |
| Hemoglobin (per 1-g/dl increment) | 9.2 | (–0.8; 19.1) | 0.07 |
| CRP (per 1-mg/L increment) | –4.3 | (–6.7; –1.9) | <10–3 |
| Estimated GFR (per 1-ml/min/1.73 m2 increment) | 0.2 | (–0.4; 0.9) | 0.46 |
| Initial HR (per 1-bpm increment) | –1.1 | (–2.2; –0.1) | 0.03 |
| ΔHR (per 1-bpm increment) | 2.8 | (1.8; 3.8) | <10–6 |
| LVEF (per 1% increment) | 1.2 | (–0.5; 2.9) | 0.15 |
| Positive chronotropic drug intake (vs no intake) | 14.2 | (–44.3; 72.6) | 0.63 |
| Negative chronotropic drug intake (vs no intake) | –25.3 | (–52.3; 1.7) | 0.07 |
N = 192. R 2 = 0.59, adjusted R 2 = 0.54
β coefficients expressed in meters
6MWD 6-minute walk distance, BMI body mass index, CI confidence interval, CRP C-reactive protein, dc diffuse cutaneous, GFR glomerular filtration rate, HR heart rate, ILD interstitial lung disease, lc limited cutaneous, LVEF left ventricle ejection fraction, PAH pulmonary arterial hypertension, SSc systemic sclerosis, Δ variation of